FDA Accepts Mesoblasts BLA Resubmission for Remestemcel-L
Filed with ASX · · 4 pages · English
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings CallStory so far
Earlier from Mesoblast
- DREAM HF Trial Published in JACC
- Half Yearly Report and Accounts
- Mesoblast Completes Resubmission of BLA to FDA for SR-aGVHD
- Extension of Undrawn US$30 million Facility
- Long-Term Survival for Acute GvHD Treatment with Remestemcel
Later from Mesoblast
- Voluntary Suspension
- Mesoblast Completes Private Placement
- Reinstatement to Official Quotation
- Third Quarter Financial Results on Form 6-K
- MSB Reports Q3 Financial Results and Operational Highlights
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast